

**EDITORIALS**

- 353 Targeting schizophrenia research to patient outcomes**  
William T. Carpenter, Jr
- 356 Understanding the glass ceiling for functional outcome in schizophrenia**  
Cameron S. Carter
- 359 Stimulant medications: how to minimize their reinforcing effects?**  
Nora D. Volkow
- 362 Are we still talking to our patients with schizophrenia?**  
Samuel J. Keith

**REVIEWS AND OVERVIEWS**

- 365 Cognitive behavior therapy for schizophrenia**  
Douglas Turkington, David Kingdon, and Peter J. Weiden

**INTROSPECTIONS**

- 374 A tension to detail**  
Samuel G. Siris

**TREATMENT IN PSYCHIATRY**

- 376 The schizophrenia prodrome**  
Tanya White, Afshan Anjum, and S. Charles Schulz

**CLINICAL CASE CONFERENCE**

- 381 The development of the self in the era of the internet and role-playing fantasy games**  
Sara E. Allison, Lisa von Wahlde, Tamra Shockley, and Glen O. Gabbard

**IMAGES IN PSYCHIATRY**

- 386 Abraham Arden Brill, 1874–1948**  
Essay by Arnold D. Richards and Paul W. Mosher

**NEW RESEARCH – ARTICLES**

- 387 PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate**  
Thomas J. Spencer, Joseph Biederman, Patrick E. Ciccone, Bertha K. Madras, Darin D. Dougherty, Ali A. Bonab, Elijah Livni, Dolly A. Parasrampur, and Alan J. Fischman
- 396 PET study evaluating dopamine D<sub>2</sub> receptor occupancy for long-acting injectable risperidone**  
Gary Remington, David Mamo, Alain Labelle, Jeffrey Reiss, Chekera Shamm, Erik Mannaert, Steve Mann, and Shitij Kapur
- 402 A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders**  
Magali Reyes, Jan Buitelaar, Paz Toren, Ilse Augustyns, and Marielle Eerdeken
- 411 Barriers to employment for people with schizophrenia**  
Robert Rosenheck, Douglas Leslie, Richard Keefe, Joseph McEvoy, Marvin Swartz, Diana Perkins, Scott Stroup, John K. Hsiao, Jeffrey Lieberman, and CATIE Study Investigators Group
- 418 Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms**  
Christopher R. Bowie, Abraham Reichenberg, Thomas L. Patterson, Robert K. Heaton, and Philip D. Harvey
- 426 The schizophrenia cognition rating scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity**  
Richard S.E. Keefe, Margaret Poe, Trina M. Walker, Joseph W. Kang, and Philip D. Harvey

- 433 Prognostic variables at intake and long-term level of function in schizophrenia**  
Steven J. Siegel, Farzin Irani, Colleen M. Brensinger, Christian G. Kohler, Warren B. Bilker, J. Daniel Ragland, Stephen J. Kanes, Ruben C. Gur, and Raquel E. Gur
- 442 Impairment in the specificity of emotion processing in schizophrenia**  
Frank Schneider, Ruben C. Gur, Kathrin Koch, Volker Backes, Katrin Amunts, N. Jon Shah, Warren Bilker, Raquel E. Gur, and Ute Habel
- 448 Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia**  
Mark J. Sergi, Yuri Rasseovsky, Keith H. Nuechterlein, and Michael F. Green
- 455 Functional and structural deficits in brain regions subserving face perception in schizophrenia**  
Toshiaki Onitsuka, Margaret A. Niznikiewicz, Kevin M. Spencer, Melissa Frumin, Noriomi Kuroki, Lisa C. Lucia, Martha E. Shenton, and Robert W. McCarley
- 463 Abnormalities of thalamic activation and cognition in schizophrenia**  
Jessica Andrews, Lei Wang, John G. Csernansky, Mokhtar H. Gado, and Deanna M. Barch
- 470 Sex differences in language dysfunction in schizophrenia**  
Deborah J. Walder, Larry J. Seidman, Nicole Cullen, Jessica Su, Ming T. Tsuang, and Jill M. Goldstein
- 478 Regional brain morphometry in patients with schizophrenia or bipolar disorder and their unaffected relatives**  
Colm McDonald, Nicolette Marshall, Pak C. Sham, Edward T. Bullmore, Katja Schulze, Ben Chapple, Elvira Bramon, Francesca Filbey, Seema Quraishi, Muriel Walshe, and Robin M. Murray

**488 Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers**

Juan Francisco Artaloytia, Celso Arango, Adrienne Lahti, Javier Sanz, Ana Pascual, Pedro Cubero, David Prieto, and Tomas Palomo

**494 Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial**

Rajesh Gopalakrishnan, K.S. Jacob, Anju Kuruvilla, B. Vasantharaj, and Jacob K. John

**500 Assessment of therapeutic misconception in older schizophrenia patients with a brief instrument**

Laura B. Dunn, Barton W. Palmer, Monique Keehan, Dilip V. Jeste, and Paul S. Appelbaum

**507 Association between the CCR5 32-bp deletion allele and late onset of schizophrenia**

Henrik Berg Rasmussen, Sally Timm, August G. Wang, Karen Søbey, Henrik Lublin, Mogens Fenger, Ralf Hemmingsen, and Thomas Werge

**512 Improving the accuracy of the diagnosis of schizophrenia by means of virtual reality**

Anna Sorkin, Daphna Weinshall, Ilan Modai, and Avi Peled

**521 Association of schizophrenia and autoimmune diseases: linkage of Danish national registers**

William W. Eaton, Majella Byrne, Henrik Ewald, Ole Mors, Chuan-Yu Chen, Esben Agerbo, and Preben Bo Mortensen

**NEW RESEARCH –  
BRIEF REPORTS**

---

**529 DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients**

Todd Lencz, Delbert G. Robinson, Ke Xu, Jenny Ekholm, Serge Sevy, Handan Gunduz-Bruce, Margaret G. Woerner, John M. Kane, David Goldman, and Anil K. Malhotra

**532 Dysbindin genotype and negative symptoms in schizophrenia**

Pamela DeRosse, Birgit Funke, Katherine E. Burdick, Todd Lencz, Jenny M. Ekholm, John M. Kane, Raju Kucherlapati, and Anil K. Malhotra

**534 BDNF Val66Met polymorphism and GAD<sub>67</sub> mRNA expression in the prefrontal cortex of subjects with schizophrenia**

Takanori Hashimoto and David A. Lewis

**537 No evidence for an effect of COMT Val158Met genotype on executive function in patients with 22q11 deletion syndrome**

Bronwyn Glaser, Martin Debbane, Christine Hinard, Michael A. Morris, Sophie P. Dahoun, Stylianos E. Antonarakis, and Stephan Eliez

**540 Cellular basis of reduced cortical reelin expression in schizophrenia**

Sharon L. Eastwood and Paul J. Harrison

**543 Antisaccade performance in monozygotic twins discordant for schizophrenia:**

**The Maudsley Twin Study**

Ulrich Ettinger, Marco Picchioni, Mei-Hua Hall, Katja Schulze, Timothea Touloupoulou, Sabine Landau, Trevor J. Crawford, and Robin M. Murray

*The American Journal of Psychiatry* is  
online at <http://ajp.psychiatryonline.org>